Could a fibrosis drug help women with adenomyosis get pregnant?
NCT ID NCT07162961
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding nintedanib, a drug that reduces scarring, to standard progesterone therapy can improve live birth rates in infertile women with adenomyosis. About 328 women aged 20-38 with frozen embryos will take either nintedanib plus progesterone or progesterone alone for three months before embryo transfer. The goal is to see if the combination leads to more successful pregnancies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nintedanib (an antifibrotic drug) plus progesterone
- What this could lead to
- If it works, this could offer a new treatment to improve pregnancy chances for women with adenomyosis who have frozen embryos.
- What could go wrong
- This is an early Phase 3 trial with no results yet. The drug may not improve live birth rates, and side effects from nintedanib are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOMYOSIS OF UTERUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a water barrier make microwave ablation safer for the womb?
- A simple diet and muscle relaxant may sharpen views in scarless hysterectomy
- Could a fibroid drug help women with adenomyosis finally achieve a live birth?
- Could a common muscle relaxant cut narcotic use after hysterectomy?
- Italian study tracks Real-World treatment of painful uterine condition
- Resident's journey to master scarless hysterectomy under the microscope